The pathogenesis of DFSP involves aberrant PDGFR signaling, making it amenable to targeted therapy with imatinib mesylate, a tyrosine kinase inhibitor that blocks PDGFR activation [4]. Here, PDGFRB is linked to dermatofibrosarcoma protuberans.